348 related articles for article (PubMed ID: 35222418)
1. Role of Serine Proteases at the Tumor-Stroma Interface.
Tagirasa R; Yoo E
Front Immunol; 2022; 13():832418. PubMed ID: 35222418
[TBL] [Abstract][Full Text] [Related]
2. Interdependence of kallikrein-related peptidases in proteolytic networks.
Beaufort N; Plaza K; Utzschneider D; Schwarz A; Burkhart JM; Creutzburg S; Debela M; Schmitt M; Ries C; Magdolen V
Biol Chem; 2010 May; 391(5):581-7. PubMed ID: 20302517
[TBL] [Abstract][Full Text] [Related]
3. Activity-based protein profiling reveals active serine proteases that drive malignancy of human ovarian clear cell carcinoma.
Mehner C; Hockla A; Coban M; Madden B; Estrada R; Radisky DC; Radisky ES
J Biol Chem; 2022 Aug; 298(8):102146. PubMed ID: 35716777
[TBL] [Abstract][Full Text] [Related]
4. Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Santibanez JF; Krstic J
Curr Protein Pept Sci; 2018; 19(12):1155-1163. PubMed ID: 29086689
[TBL] [Abstract][Full Text] [Related]
5. The mouse testis is the source of various serine proteases and serine proteinase inhibitors (SERPINs): Serine proteases and SERPINs identified in Leydig cells are under gonadotropin regulation.
Odet F; Verot A; Le Magueresse-Battistoni B
Endocrinology; 2006 Sep; 147(9):4374-83. PubMed ID: 16740973
[TBL] [Abstract][Full Text] [Related]
6. Interactions of serine proteases with cultured fibroblasts.
Cunningham DD; Van Nostrand WE; Farrell DH; Campbell CH
J Cell Biochem; 1986; 32(4):281-91. PubMed ID: 3543029
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Dong Z; Saliganan AD; Meng H; Nabha SM; Sabbota AL; Sheng S; Bonfil RD; Cher ML
Neoplasia; 2008 May; 10(5):439-49. PubMed ID: 18472961
[TBL] [Abstract][Full Text] [Related]
8. Multiple pathways of cell invasion are regulated by multiple families of serine proteases.
Del Rosso M; Fibbi G; Pucci M; D'Alessio S; Del Rosso A; Magnelli L; Chiarugi V
Clin Exp Metastasis; 2002; 19(3):193-207. PubMed ID: 12067200
[TBL] [Abstract][Full Text] [Related]
9. [The serine proteases and their function in neuronal death processes].
Fuster Lluch O; Galindo MF; Ceña V; Jordán J
Rev Neurol; 2004 Mar 1-15; 38(5):449-57. PubMed ID: 15029525
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
Schmitt M; Jänicke F; Moniwa N; Chucholowski N; Pache L; Graeff H
Biol Chem Hoppe Seyler; 1992 Jul; 373(7):611-22. PubMed ID: 1515091
[TBL] [Abstract][Full Text] [Related]
11. Cancer invasion and tissue remodeling--cooperation of protease systems and cell types.
Danø K; Rømer J; Nielsen BS; Bjørn S; Pyke C; Rygaard J; Lund LR
APMIS; 1999 Jan; 107(1):120-7. PubMed ID: 10190288
[TBL] [Abstract][Full Text] [Related]
12. The role of type II transmembrane serine protease-mediated signaling in cancer.
Tanabe LM; List K
FEBS J; 2017 May; 284(10):1421-1436. PubMed ID: 27870503
[TBL] [Abstract][Full Text] [Related]
13. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity.
Montgomery N; Hill A; McFarlane S; Neisen J; O'Grady A; Conlon S; Jirstrom K; Kay EW; Waugh DJ
Breast Cancer Res; 2012 May; 14(3):R84. PubMed ID: 22621373
[TBL] [Abstract][Full Text] [Related]
14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
15. Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
Dorn J; Beaufort N; Schmitt M; Diamandis EP; Goettig P; Magdolen V
Crit Rev Clin Lab Sci; 2014 Apr; 51(2):63-84. PubMed ID: 24490956
[TBL] [Abstract][Full Text] [Related]
16. Plasticity-related serine proteases in the brain (review).
Yoshida S; Shiosaka S
Int J Mol Med; 1999 Apr; 3(4):405-9. PubMed ID: 10085414
[TBL] [Abstract][Full Text] [Related]
17. Modulation of smooth muscle responses by serine proteases and related enzymes.
Fareed J; Kindel G; Kumar A
Semin Thromb Hemost; 1986 Oct; 12(4):265-76. PubMed ID: 3097826
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.
Botkjaer KA; Deryugina EI; Dupont DM; Gårdsvoll H; Bekes EM; Thuesen CK; Chen Z; Ploug M; Quigley JP; Andreasen PA
Mol Cancer Res; 2012 Dec; 10(12):1532-43. PubMed ID: 23038812
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Mukai S; Yamasaki K; Fujii M; Nagai T; Terada N; Kataoka H; Kamoto T
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32290402
[TBL] [Abstract][Full Text] [Related]
20. Remodelling of the tumour microenvironment by the kallikrein-related peptidases.
Srinivasan S; Kryza T; Batra J; Clements J
Nat Rev Cancer; 2022 Apr; 22(4):223-238. PubMed ID: 35102281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
